Sitagliptin-Associated Drug Allergy: Review of Spontaneous Adverse Event Reports

Desai, Shrey K; Brinker, Allen; Swann, Joslyn; Iyasu, Solomon

doi:10.1001/archinternmed.2010.188

Cited by 40 publications

(36 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neither linagliptin nor sitagliptin, which was responsible for 4 cases of DPP-4 inhibitor-associated BP in the literature [5,8,9], showed such adverse reactions in preclinical studies [17,18]. A review of sitagliptin-related adverse event reports from the United States Food and Drug Administration database between October 2006 and November 2008 [19] describes 2 cases of Stevens-Johnson syndrome, 2 cases of toxic epidermal necrolysis, and 22 cases of ‘bullous, desquamative, blistering, exfoliative, urticarial, or exanthematous skin reactions'. According to the referred article, no additional efforts have been made to further differentiate these skin reactions.…”

Section: Discussionmentioning

confidence: 99%

Three Cases of Bullous Pemphigoid Associated with Dipeptidyl Peptidase-4 Inhibitors - One due to Linagliptin

et al. 2016

View full text Add to dashboard Cite

Background: Bullous pemphigoid (BP) is an acquired subepidermal autoimmune blistering disease in which there are humoral and cellular responses against the BP180 and BP230 antigens. Dipeptidyl peptidase (DPP)-4 inhibitors enhance endogenous glucagon peptide-1 and glucose-dependent insulinotropic polypeptide secretion with food intake, which leads to insulin secretion, as well as to the reduction of glucagon secretion. Recently, several cases of DPP-4 inhibitor-associated BP have been reported. Objectives: To report 3 cases of DPP-4 inhibitor-associated BP, one of which is due to linagliptin use, as well as to review all currently published cases of DPP-4 inhibitor-associated BP. Case Reports: Three patients diagnosed with BP at our department showed a clear temporal relationship between the introduction of DPP-4 for the treatment of diabetes and the onset of BP. One case was due to linagliptin use, while the other 2 cases were due to an association with vildagliptin-metformin use. Conclusions: This is the first report of linagliptin-associated BP. Furthermore, 2 other cases of vildagliptin-associated BP are reported.

show abstract

Section: Discussionmentioning

confidence: 99%

Three Cases of Bullous Pemphigoid Associated with Dipeptidyl Peptidase-4 Inhibitors - One due to Linagliptin

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The authors proposed that an altered immune function status could be the underlying mechanism for angioedema and other hypersensitivity reactions to sitagliptin. 7 More recent evidence raises other questions regarding the combined use of DPP-4I and ACEI. An interactive hemodynamic effect occurs with with combined therapy, and, depending on the extent of ACE inhibition, blood pressure may actually be increased.…”

Section: Clinical Reports and Correlates Of Angioedema With Dpp-4 Inhmentioning

confidence: 99%

DPP-4 inhibitors and angioedema: a cause for concern?

Byrd¹,

Minor²,

El‐Sayed³

et al. 2011

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

“…4 Since the release of gliptins into the market they have been linked to several skin reactions in humans, most serious of which is Steven Johnson syndrome. 5 The enzyme DDP-IV has been shown to be ubiquitously expressed in almost every organ system, including the skin. 6 …”

Section: Introductionmentioning

confidence: 99%

Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature.

Attaway

Mersfelder

Vaishnav

et al. 2014

J Dermatol Case Rep

View full text Add to dashboard Cite

show abstract

Sitagliptin-Associated Drug Allergy: Review of Spontaneous Adverse Event Reports

Cited by 40 publications

References 2 publications

Three Cases of Bullous Pemphigoid Associated with Dipeptidyl Peptidase-4 Inhibitors - One due to Linagliptin

Three Cases of Bullous Pemphigoid Associated with Dipeptidyl Peptidase-4 Inhibitors - One due to Linagliptin

DPP-4 inhibitors and angioedema: a cause for concern?

Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature.

Contact Info

Product

Resources

About